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ABSTRACT
Methicillin-resistant Staphylococcus aureus (MRSA) is well-recognised as a major cause of infection in the
healthcare setting but, even more worryingly, is now emerging in the community. The glycopep-
tides—notably vancomycin—have traditionally been the mainstay of treatment of MRSA but overuse
has led to the emergence of vancomycin-intermediate and vancomycin-resistant MRSA (VISA and
VRSA, respectively). Although the mechanisms underlying vancomycin resistance are not yet fully
understood, changes to the bacterial cell wall—the site of action of the glycopeptides—are believed to be
key. Recent evidence also supports the transfer of genetic material among bacteria as contributing to the
development of VRSA. Based on the cases identified to date, risk factors for the development of VRSA
may include older age, compromised blood flow to the lower limbs, and the presence of chronic ulcers.
The true extent of the problem, however, remains to be determined—it is likely that many cases of VISA
and VRSA infection go undetected because of suboptimal screening programmes and possible
limitations of automated and non-automated detection methods. Effective screening directed at those
patients considered to be most at risk should therefore be a priority. Not surprisingly, the spread of
MRSA from the hospital to the community setting, coupled with the emergence of VISA and VRSA, has
become a major cause of concern among clinicians and microbiologists. The treatment options available
for these infections are now severely compromised and thus new classes of antimicrobial agents
effective against MRSA, VISA and VRSA are urgently required.
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INTRODUCTION
Serious infections caused by Staphylococcus aureus
are a worldwide phenomenon and occur in both
the hospital and community settings. Initially,
penicillin G was an effective therapy option for
S. aureus infections. However, the emergence of
penicillin resistance in S. aureus isolates over the
past 50 years has had an impact on how such
infections are treated [1]. The development of
methicillin resistance, in particular, has been a
cause for concern among physicians and micro-
biologists in recent years and effective treatment
options are diminishing. In the USA, most clinical
S. aureus isolates are resistant to penicillin (95%)
and over half are resistant to methicillin; the
prevalence of methicillin-resistant S. aureus
(MRSA) in Europe is also a problem [2,3]. The
situation is complicated by the recent increase in
serious infections caused by Panton–Valentine
leukocidin toxin-producing community-acquired
MRSA in the USA [4–7].
Until recently, the glycopeptide vancomycin
represented a uniquely effective solution for
treating infections caused by methicillin-resistant
pathogens, including S. aureus. However, the
overuse of this antibiotic in oral form for condi-
tions such as pseudomembranous colitis has
inevitably changed this situation. The first clinical
isolate of vancomycin-intermediate-resistant
S. aureus (VISA) was identified in 1997, and these
strains have now been reported worldwide [8,9].
Although VISA strains have hitherto been
thought to be rare, a recent study from Turkey,
in which 46 of 256 (18%) MRSA isolates obtained
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(mainly from blood and pus) between 1998 and
2002 showed the VISA phenotype, suggests that
their incidence may be on the rise [10]. More
recently, there have been reports of vancomycin-
resistant S. aureus (VRSA), which is even more
alarming, as these isolates demonstrate complete
vancomycin resistance [11–14].
This review will briefly touch upon MRSA and
its prevalence in both the hospital and community
settings, before focusing on the emergence of
VISA and VRSA onto the infectious disease scene.
The mechanism of vancomycin non-susceptibil-
ity, the possible presence of resistant strains in
healthy carriers, and laboratory methods for
determining vancomycin susceptibility will also
be discussed.
MRSA: A PROBLEM IN BOTH THE
HOSPITAL AND COMMUNITY
SETTINGS
MRSA is not only recognised as a major cause of
infections within the healthcare setting but is also
emerging as a cause of infections in non-health-
care settings (i.e., within the community). For
example, MRSA clones were found in an outbreak
of abscesses reported recently in a professional US
football team [6]. MRSA isolates from 9% of the
team were compared with other community and
hospital isolates. All were found to be carrying
the gene for Panton–Valentine leukocidin and the
gene complex for staphylococcal-cassette-chromo-
some mec (SCCmec) type IVa resistance, which are
known to cause skin and soft tissue infections.
Isolates were susceptible to most antimicrobial
agents, but not b-lactams and macrolides [6].
MRSA strains causing life-threatening bacterae-
mia in infants treated from birth in a neonatal
intensive care unit have also demonstrated the
genetic traits of community-associated MRSA
[15]. During 2003, 17 infants with bacteraemia
due to S. aureus were tested for methicillin resist-
ance: eight infants (47%) tested positive for
MRSA, and isolates from six of these infants
(75%) carried the SCCmec gene characteristic of
community MRSA; four isolates were type IVa.
All of the isolates carrying the SCCmec gene were
resistant to b-lactam antibiotics and erythromy-
cin, and one was also resistant to clindamycin.
Seven (88%) of eight infants had septic shock, and
vancomycin was used as initial therapy. Despite
this, three infants (38%) died, and three had
complications requiring prolonged antimicrobial
therapy.
Worryingly, the above reports are likely to be
just two examples of a more widespread clinical
problem. Indeed, three MRSA pandemic clones
have been traced to original isolates from Den-
mark, and dramatic increases in methicillin resist-
ance among S. aureus strains, as well as increased
numbers of MRSA infections, have been linked to
the expanding reservoir of community-onset
MRSA [16,17]. Furthermore, increased use of
vancomycin to treat MRSA will result in increased
vancomycin selective pressure in the community,
which, in turn, may lead to more strains of VISA
and VRSA.
STAPHYLOCOCCAL RESISTANCE:
FROM VISA TO VRSA
The concentration of vancomycin required to
inhibit most strains ofS. aureus is typically between
0.5 and 2 mg ⁄L [18]. S. aureus isolates for which
vancomycin MICs are 8–16 mg ⁄L are currently
classified as vancomycin-intermediate, and iso-
lates for which vancomycin MICs are ‡ 32 mg ⁄L
are classified as vancomycin-resistant [18]. How-
ever, the Clinical and Laboratory Standards Insti-
tute (CLSI, formerly the National Committee for
Clinical Laboratory Standards) recommended that
S. aureus isolates with vancomycin MICs of 4 mg ⁄L
should be treated as susceptible. The Centers for
Disease Control and Prevention (CDC) recommen-
dations, on the other hand, are to consider these
strains as potentially intermediate. They advocate
retesting and investigation into the patient’s
history for vancomycin treatment and possible
response to vancomycin therapy [18]. There is also
a question as to whether systemic infections (e.g.,
endocarditis) caused by S. aureus strains with
vancomycin MICs of 2 mg ⁄L are truly clinically
vancomycin susceptible [19]. Teicoplanin and
vancomycin belong to the glycopeptide class of
antibiotics and may therefore be expected to have a
common resistance mechanism; the term glyco-
peptide-intermediate S. aureus is therefore syn-
onymous with VISA [20].
EMERGENCE OF HETEROGENEOUS VISA
AND VISA
Over the last decade, S. aureus strains with
elevated vancomycin MICs have emerged [21].
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In 1997, a Japanese group identified the first
heterogeneous VISA strain—the precursor to
VISA—with reduced susceptibility to vancomycin
[22]. The heterogeneous strain was isolated from
the sputum of a 64-year-old man with MRSA
pneumonia that was unresponsive after 12 days
of vancomycin treatment. The MRSA (Mu3) strain
was grown in a drug-free medium, and produced
a sub-population of cells with varying degrees of
vancomycin resistance, thus demonstrating nat-
ural heterogeneity, or variability, in susceptibility
to vancomycin. Mu3 produced sub-clones in the
presence of vancomycin, with resistance roughly
proportional to the concentrations of vancomycin
used. Selection of Mu3 sub-clones with 8 mg ⁄L or
more of vancomycin gave rise to sub-clones with
a vancomycin MIC of 8 mg ⁄L at a frequency of
10)6 CFU ⁄mL or higher.
True VISA was also first reported in Japan in
1997, and the first isolate was obtained from a
surgical wound in a 4-month-old infant who had
undergone open-heart surgery [8]. Two weeks
after surgery, the patient became febrile and
developed a purulent discharge from the surgical
incision site. Despite vancomycin treatment for
29 days, the fever and discharge persisted. At this
stage, an aminoglycoside (arbekacin) was added
to the vancomycin treatment regimen for 12 days;
the wound healed and antimicrobial therapy was
discontinued. However, 12 days later the incision
site appeared inflamed and an abscess developed.
This was treated with arbekacin plus ampicillin–
sulbactam, and debridement of the subcutaneous
abscess was performed. The debridement sample
revealed an MRSA strain (Mu50) with a vanco-
mycin MIC of 8 mg ⁄L by the broth microdilution
method. This was the first clinical strain of
S. aureus to demonstrate this level of vancomycin
resistance and was quickly followed by reports of
VISA emergence in other countries, including the
USA, prompting a flurry of activity aimed at
limiting its spread [9,20].
EMERGENCE OF VRSA
To date, four VRSA isolates have been identified
in the USA: two from Michigan, and one each
from Pennsylvania and New York [11–14]. The
first clinical isolate was identified from a swab
taken from the catheter exit site of a 40-year-old
man in Michigan with diabetes, peripheral vas-
cular disease and chronic renal failure in June
2002 [13]. Prior to this, the patient had been
treated for chronic foot ulceration, and had been
the recipient of multiple courses of antimicrobial
therapy, including vancomycin. He had devel-
oped MRSA following the amputation of a gan-
grenous toe in April 2002, and was treated with
vancomycin and rifampicin. S. aureus strains
resistant to vancomycin (MIC > 128 mg ⁄L) and
oxacillin (MIC > 16 mg ⁄L) were isolated from the
exit site, which appeared to be healed a week after
the removal of the catheter, but the patient’s
chronic foot ulcer appeared to be infected. VRSA,
vancomycin-resistant Enterococcus faecalis and
Klebsiella oxytoca were isolated from the ulcer.
This strain exhibited high resistance to vancomy-
cin (MIC > 128 mg ⁄L by broth microdilution).
Shortly after this report, another clinical isolate
of VRSA was described in Hershey, Pennsylvania,
in September 2002 with an MIC of 32 mg ⁄L by
broth microdilution testing [14]. The strain was
isolated from a chronic foot ulcer in a 70-year-old
morbidly obese hypertensive male patient who
had received multiple courses of antibiotics (other
than vancomycin) in the past and with a recent
history of somnolence, intermittent fever, chills,
malaise, night sweats and dyspnoea on exertion
for several weeks before presentation [14]. A third
isolate of VRSA was obtained from a urine sample
and the urinary tract catheter of an elderly patient
in long-term care in New York in 2004
(MIC 32 mg ⁄L by broth microdilution testing)
[12]. In addition, vancomycin-resistant enterococ-
ci were isolated from multiple sites in this patient
(F. C. Tenover, personal communication).
A fourth VRSA isolate has also recently been
reported (March 2005), the second reported from
Michigan [11]. VRSA (MIC 256 mg ⁄L) was isola-
ted from a gangrenous toe wound in a 78-year-old
male with a history of coronary artery disease,
type 2 diabetes, peripheral vascular disease,
neuropathy, chronic renal insufficiency and
obstructive uropathy. Prior to the toe wound,
the patient had received vancomycin for most of
the 9 weeks following surgery for an aortic valve
replacement procedure. Although a vancomycin-
susceptible E. faecalis isolate was recovered from
the toe wound prior to amputation, a vancomy-
cin-resistant E. faecalis isolate was recovered from
a surveillance rectal culture in the same patient.
Thus, vancomycin-resistant enterococci have been
isolated from three of the four VRSA patients, and
in-vivo transfer of the VanA gene could have
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occurred in this setting. The pathogenesis of gene
transfer in the Hershey patient is unknown.
A comparison of the first three of these VRSA
strains to emerge is shown in Table 1. Factors that
may be associated with VRSA infection are age, a
compromised blood supply to the lower legs
caused by conditions such as hypertension and
diabetes, chronic foot ulcers and a history of prior
vancomycin treatment.
MECHANISMS OF VANCOMYCIN
RESISTANCE
Glycopeptides (i.e., vancomycin and teicoplanin)
exert their antimicrobial effects by inhibiting
synthesis of the S. aureus cell wall [23]. Cell wall
thickening and, potentially, the transfer of genetic
Table 1. Comparison of three vancomycin-resistant Sta-
phylococcus aureus (VRSA) strains
VRSA strain
Michigana Hersheyb New Yorkc
MIC 1024 mg ⁄L 32 mg ⁄L 64 mg ⁄L
History of
vancomycin
treatment
Yes No ?
VRE Yes No Yesd
Plasmid 60 kb 120 kb 120 kb
Transfer No No ?
Carrier No No ?
VRE, vancomycin-resistant enterococci.
aAppelbaum and Bozdogan [36].
bTenover et al. [14].
cKacica and McDonald [12].
dF. C. Tenover, personal communication.
Susceptible cell:
Cell wall synthesis 
is inhibited and 
glycopeptides 
have access to 
cell wall synthesis 
sites
VISA:
Cell wall synthesis 
continues and 
glycopeptides are 
unable to access 
cell wall synthesis 
sites
Cell wall
precursor with
D-Ala-D-Ala
D-Ala-D-Ala
terminus of
uncross-linked
peptidoglycan
D-Ala terminus
of cross-linked
peptidoglycan
Glycopeptide
Cell wall
Cell membrane
Fig. 1. Cell wall thickening is a feature of VISA. Reproduced from Sieradzki et al. [24] with permission from The American
Society for Biochemistry and Molecular Biology, Inc.
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material are currently thought to underlie the
development of vancomycin resistance. Vanco-
mycin acts by binding irreversibly to the terminal
D-alanyl-D-alanine of bacterial cell wall precur-
sors, inhibiting cell wall production by attacking
the sites responsible for cell wall synthesis [24].
Resistance in VISA strains is thought to occur
as a result of changes in peptidoglycan synthesis.
VISA strains synthesise extra peptidoglycan with
increased quantities of D-alanyl-D-alanine resi-
dues. These residues bind vancomycin molecules
and effectively sequester them, thereby prevent-
ing them from reaching their bacterial target (Fig.
1) [24,25]. Furthermore, the newly altered cell
walls containing bound vancomycin further
impede the progress of drug molecules.
A number of studies have investigated the role
of the bacterial cell wall in vancomycin suscepti-
bility in S. aureus [26–28]. Increased resistance to
vancomycin in Mu50 S. aureus was associated
with accelerated peptidoglycan synthesis, thick-
ened cell walls, an increased proportion of gluta-
mine non-amidated muropeptides and reduced
peptidoglycan cross-linking [26]. Thickening of
cell walls correlated with the trapping of vanco-
mycin in the outer layers and was considered to
be the mechanism of resistance [26]. The Mu3
isolates also displayed vancomycin resistance,
with cell wall thickening and peptidoglycan
synthesis activities, although neither of these
occurred to the same extent as observed in
Mu50 isolates [26]. Other studies have suggested
that structural and ⁄ or metabolic changes in cell
wall teichoic acids may also play a role in the
resistance mechanism by reducing the rate of cell
wall degradation (instead of increasing the rate of
cell wall synthesis), thus maintaining a correlation
between wall thickness and decreasing suscepti-
bility to vancomycin [29].
Recently, there has been evidence to support
the exchange of genetic material among VRSA
bacteria [20,25,30–32]. Genetic analyses suggest
that the in-vivo transfer of vancomycin resistance
from E. faecalis to an MRSA strain occurred to
produce the Michigan VRSA isolate [30,31].
Acquisition of the vanA gene in the Michigan
isolate occurred via the interspecies transfer of
Tn1546 (the vanA transposon, harboured within a
multiresistant conjugative plasmid) from co-iso-
lated vancomycin-resistant E. faecalis [30]. This
isolate achieved vancomycin resistance by
altering the terminal peptide of D-alanyl-D-alan-
ine to D-alanyl-D-lactate, which only occurs with
exposure to low concentrations of vancomycin,
and the new dipeptide seems to have a reduced
affinity for vancomycin (Fig. 2) [25].
VANCOMYCIN RESISTANCE IN
HEALTHY CARRIERS
In a recent Brazilian study, vancomycin-resistant
strains were detected among coagulase-negative
staphylococci, both inside and outside the hospi-
tal environment [33]. All strains (Staphylococcus
capitis, Staphylococcus ureolyticus, Staphylococcus
hemolyticus and Staphylococcus epidermidis) dem-
onstrated unstable heteroresistance to vanco-
mycin, and had significantly thicker cell walls
than the control strains (p < 0.001). Unstable
heteroresistance to vancomycin in these strains
means that, if subcultured several times, they
tend to revert to vancomycin susceptibility [33].
However, in the presence of vancomycin, these
revertant strains select for strains of vancomycin-
resistant staphylococci at very high frequencies.
This implies that, although these strains of
vancomycin-resistant staphylococci may not dis-
seminate with stable resistance, they can readily
revert to vancomycin resistance when they are
exposed to this antibiotic [33].
The presence of coagulase-negative staphylo-
coccal isolates in healthy carriers is of concern,
particularly outside the hospital environment, as
there has been no systematic screening pro-
gramme for staphylococcal vancomycin resistance
Vancomycin-susceptible enterococci
Vancomycin-resistant enterococci
D-Ala-D-Ala
D-Ala-D-Lac
D-Ala-D-Ala Glycopeptide
Glycopeptide
Fig. 2. Mechanism of vancomycin resistance in vancomy-
cin-resistant Staphylococcus aureus (VRSA). Adapted from
Murray [37].
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in patients likely to be at the greatest risk (i.e.,
those in long-term care or nursing homes, or those
with chronic leg or decubitus ulcers). Thus, we
have no knowledge of how widespread this
problem is until these urgently needed studies
are undertaken. The consequence of reduced
vancomycin susceptibility is clearly an increased
possibility of antimicrobial failure. The high
prevalence of MRSA and glycopeptide use, both
thought to be risk factors for VRSA, make the
widespread dissemination of these organisms an
alarming and realistic possibility [34].
TESTING FOR VANCOMYCIN
SUSCEPTIBILITY
Non-automated methods that are acceptable for
detecting VISA and VRSA are: CLSI broth micro-
dilution, agar dilution and Etest with 0.5 McFar-
land standard to prepare inoculum (AB Biodisk,
Piscataway, NJ, USA) [18]. The Etest has the
advantage of showing small colonies around one
or more zones of inhibition and is considered to
be among the most discriminatory of these tests.
Disk diffusion alone may be acceptable for VRSA
but not for the detection of VISA [18]. Fig. 3
shows disk diffusion and Etest analysis of the
Hershey VRSA isolate on Mueller–Hinton agar
[14].
Automated methods [e.g., Vitek and Micro-
Scan (bioMerieux, Hazelwood, MO, USA)] are
not as effective, with two-thirds of confirmed
VRSA isolates not being reliably detected by
automated testing systems [18]. Neither automa-
ted method accurately identified Hershey (Penn-
sylvania) and New York VRSAs with
vancomycin MICs of 32–64 mg ⁄L [11,14]. Thus,
laboratories using these methods must also use a
vancomycin agar screening plate test with brain–
heart infusion containing 6 mg ⁄L vancomycin
[18].
Some S. aureus strains with vancomycin MICs
of 4 mg ⁄L, or even 2 mg ⁄L, may not be truly
clinically susceptible to vancomycin. Taking this
into consideration, it may be timely for the CLSI
and CDC to lower their recommendation for the
concentration of vancomycin in screening plates.
In Europe, the Socie´te´ Franc¸aise de Microbiologie
(SFM) and the Deutsches Institut fu¨r Normung
(DIN) recommend screening plates with 6 mg ⁄L
teicoplanin; this concentration is considered to be
too high and a teicoplanin concentration of 1–
2 mg ⁄L would be more appropriate. The Hershey
(Pennsylvania) VRSA isolate had a teicoplanin
MIC of 4 mg ⁄L [35].
CONCLUSIONS
MRSA has spread into the community and is
now distributed across the world. Increased
numbers of MRSA infections, plus greater meth-
icillin resistance levels within MRSA isolates,
have been linked to the expanding reservoir of
these strains in the community. Increased use of
vancomycin has led to selective pressure, and
the subsequent appearance of VISA followed by
VRSA has sparked alarm among physicians and
microbiologists. Four isolated cases of VRSA
infection have been reported to date and all of
these have been in the USA. Based on this very
small sample size, it appears that VRSA is more
likely to affect older patients with a compro-
mised blood supply to lower limbs and chronic
ulcers. Directed screening of patients most at risk
is urgently required to assess the extent of the
VISA and VRSA problem as well as vancomycin
non-susceptibility in coagulase-negative staphy-
lococci. Caution must be exercised in the use of
detection methods, as automated techniques
alone are ineffective in detecting many of these
isolates. With increasing antimicrobial resistance
Fig. 3. Disk diffusion and Etest analysis of the Hershey
VRSA isolate on Mueller–Hinton agar. A zone of complete
growth inhibition can be observed within a wider zone of
reduced growth around both the 30-lg vancomycin disk
and the Etest strip. The arrows indicate the presence of
small colonies within the inner zone of inhibition that
impact on the reading of the MIC result. Reproduced from
Tenover et al. [14] with permission from the American
Society for Microbiology.
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among bacteria, there is clearly a need for new
classes of antibiotic with different mechanisms of
action that are effective against MRSA, VISA and
VRSA.
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